Company: BIVIW
Filing Date: 2025-09-25
Form Type: DEF 14A
Source: 0001520138-25-000287
Chunk: 14

Company: BIOVIE INC.
Filing Date: 2025-09-25
Form: DEF 14A
Chunk 14
---
), which he transformed into a leading healthcare
data and analytics firm. Prior to that, Jim was CEO of IHS Cambridge Energy Research Associates (IHS CERA), a recognized leader in energy
industry subscription information products, and formerly the President of Strategic Decisions Group (SDG), a leading global strategy consultancy.
Mr. Lang holds a BS summa cum laude in electrical and computer engineering from the University of New Hampshire and an MBA with Distinction
from the Tuck School of Business. Jim Lang currently also serves as a Director at OptimizeRX (OPRX), a Nasdaq listed Company.

Jim Lang’s qualifications to serve on our Board of Directors are
primarily based on his decades of experience as a strategy consultant, broad industry expertise, and senior-level management experience
running several healthcare and information technology companies.

Mr. Cuong Do has served on the Company’s Board of Directors
since 2016 and was appointed the Company’s Chief Executive Officer (“CEO”) and President in 2021. He previously served
as President, Global Strategy Group at Samsung from 2015 to 2020. Mr. Do helped set the strategic direction for Samsung’s diverse
business portfolio. Prior to that, he was the Chief Strategy Officer for Merck from 2011 to 2014, Tyco Electronics from 2009 to 2011,
and Lenovo from 2007 to 2009. Mr. Do is a former senior partner at McKinsey & Company, where he spent 17 years and helped build the
healthcare, high tech and corporate finance practices. He holds a BA from Dartmouth College, and an MBA from the Tuck School of Business
at Dartmouth.

We believe Mr. Do’s qualifications to serve on our Board of Directors
and as the CEO and President are primarily based on his decades of experience as an executive in the pharma, biotech, and other high technology
industries and his extensive experience in strategy, corporate finance practice and the development of companies in all stages.

Mr. Kameel Faraghas served as a director of the Company since
2025. Most recently, he was Chief Financial Officer, Treasurer and head of business operations at Aspen Neuroscience from 2021 to 2025,
where he oversaw tripling the company’s headcount, secured over $150 million in financing, built manufacturing infrastructure and
prepared the company for clinical data and a potential future public offering. Prior to that, he served as Senior Vice President, Finance
at